These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 9710365)
1. The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance. Laube H; Linn T; Heyen P Exp Clin Endocrinol Diabetes; 1998; 106(3):231-3. PubMed ID: 9710365 [TBL] [Abstract][Full Text] [Related]
3. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Chiasson JL; Josse RG; Leiter LA; Mihic M; Nathan DM; Palmason C; Cohen RM; Wolever TM Diabetes Care; 1996 Nov; 19(11):1190-3. PubMed ID: 8908378 [TBL] [Abstract][Full Text] [Related]
4. Effects of acarbose treatment on markers of insulin sensitivity and systemic inflammation. Rudovich NN; Weickert MO; Pivovarova O; Bernigau W; Pfeiffer AF Diabetes Technol Ther; 2011 Jun; 13(6):615-23. PubMed ID: 21488802 [TBL] [Abstract][Full Text] [Related]
5. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Chiasson JL Diabet Med; 1996; 13(3 Suppl 2):S23-4. PubMed ID: 8689858 [TBL] [Abstract][Full Text] [Related]
6. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. Chiasson JL; Gomis R; Hanefeld M; Josse RG; Karasik A; Laakso M Diabetes Care; 1998 Oct; 21(10):1720-5. PubMed ID: 9773737 [TBL] [Abstract][Full Text] [Related]
7. The effect of acarbose on insulin resistance in obese hypertensive subjects with normal glucose tolerance: a randomized controlled study. Rachmani R; Bar-Dayan Y; Ronen Z; Levi Z; Slavachevsky I; Ravid M Diabetes Obes Metab; 2004 Jan; 6(1):63-8. PubMed ID: 14686965 [TBL] [Abstract][Full Text] [Related]
8. Will acarbose improve the metabolic abnormalities of insulin-resistant type 2 diabetes mellitus? Scott R; Lintott CJ; Zimmet P; Campbell L; Bowen K; Welborn T Diabetes Res Clin Pract; 1999 Mar; 43(3):179-85. PubMed ID: 10369427 [TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. Coniff RF; Shapiro JA; Seaton TB Arch Intern Med; 1994 Nov; 154(21):2442-8. PubMed ID: 7979840 [TBL] [Abstract][Full Text] [Related]
10. Effect of acarbose on glucose intolerance in patients with non-insulin-dependent diabetes mellitus. Noda K; Umeda F; Nawata H Diabetes Res Clin Pract; 1997 Aug; 37(2):129-36. PubMed ID: 9279483 [TBL] [Abstract][Full Text] [Related]
11. Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients. Fischer S; Patzak A; Rietzsch H; Schwanebeck U; Köhler C; Wildbrett J; Fuecker K; Temelkova-Kurktschiev T; Hanefeld M Diabetes Obes Metab; 2003 Jan; 5(1):38-44. PubMed ID: 12542723 [TBL] [Abstract][Full Text] [Related]
12. Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians. Nagi DK; Mohamed Ali V; Jain SK; Walji S; Yudkin JS Diabet Med; 1996 Jan; 13(1):59-64. PubMed ID: 8741814 [TBL] [Abstract][Full Text] [Related]
13. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study. Lam KS; Tiu SC; Tsang MW; Ip TP; Tam SC Diabetes Care; 1998 Jul; 21(7):1154-8. PubMed ID: 9653611 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. Hoffmann J; Spengler M Am J Med; 1997 Dec; 103(6):483-90. PubMed ID: 9428831 [TBL] [Abstract][Full Text] [Related]
15. Low-dose acarbose improves glycemic control in NIDDM patients without changes in insulin sensitivity. Jenney A; Proietto J; O'Dea K; Nankervis A; Traianedes K; D'Embden H Diabetes Care; 1993 Feb; 16(2):499-502. PubMed ID: 8432223 [TBL] [Abstract][Full Text] [Related]
16. Treatment of poorly controlled non-insulin-dependent diabetic patients with Acarbose. Scott RS; Knowles RL; Beaven DW Aust N Z J Med; 1984 Oct; 14(5):649-54. PubMed ID: 6397178 [TBL] [Abstract][Full Text] [Related]
17. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study. Coniff RF; Shapiro JA; Robbins D; Kleinfield R; Seaton TB; Beisswenger P; McGill JB Diabetes Care; 1995 Jun; 18(6):817-24. PubMed ID: 7555508 [TBL] [Abstract][Full Text] [Related]
18. A study of the effects of acarbose on glucose metabolism in patients predisposed to developing diabetes: the Dutch acarbose intervention study in persons with impaired glucose tolerance (DAISI). Nijpels G; Boorsma W; Dekker JM; Kostense PJ; Bouter LM; Heine RJ Diabetes Metab Res Rev; 2008; 24(8):611-6. PubMed ID: 18756586 [TBL] [Abstract][Full Text] [Related]
19. Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance. Derosa G; Cicero AF; D'Angelo A; Ragonesi PD; Ciccarelli L; Fogari E; Salvadeo SA; Ferrari I; Gravina A; Fassi R; Fogari R Clin Drug Investig; 2006; 26(9):529-39. PubMed ID: 17163286 [TBL] [Abstract][Full Text] [Related]
20. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Coniff RF; Shapiro JA; Seaton TB; Bray GA Am J Med; 1995 May; 98(5):443-51. PubMed ID: 7733122 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]